Association between insulin, glucagon, high sensitive c-reactive protein, insulin resistance with visceral adipose tissue-derived serine protease inhibitor (VASPIN) in obese population

I Made Pande Dwipayana; Wira Gotera; Ketut Suastika; I Wayan Putu Sutirta Yasa; Anak Agung Gede Budhiarta; Made Ratna Saraswati; I Made Siswadi Semadi; Ida Bagus Aditya Nugraha

doi:10.15562/bmj.v11i3.3910

Association between insulin, glucagon, high sensitive c-reactive protein, insulin resistance with visceral adipose tissue-derived serine protease inhibitor (VASPIN) in obese population

I Made Pande Dwipayana ,

Wira Gotera ,

Ketut Suastika ,

I Wayan Putu Sutirta Yasa ,

Anak Agung Gede Budhiarta ,

Made Ratna Saraswati ,

I Made Siswadi Semadi ,

Ida Bagus Aditya Nugraha ,

pdf |
DOI: https://doi.org/10.15562/bmj.v11i3.3910 |
Published: 2022-11-26

Abstract

Background: Obesity is an inflammatory condition that results in an increase in high sensitive C-Reactive Protein (hs-CRP), a risk for insulin resistance (IR). Vaspin has the effect of increasing insulin receptor sensitivity and on the other hand is a compensatory response to insulin resistance, one of which is measured by homeostasis models assessment-insulin resistance (HOMA-IR). This study was an analytical cross-sectional observational design, to determine the association between insulin, glucagon, CRP, and HOMA-IR levels with serum vaspin in obesity.

Method: This study is an analytical study with a cross-sectional design. Criteria of inclusion were subjects in the range 18-60 years Denpasar citizen with BMI above 25 kg/m² and willing to be involved in this study, while exclusion criteria were with either chronic conditions or acute inflammation such as infection, cancer, tumor, or chronic disease which is altered and threatening life. Correlation tests using spearman analysis.

Results: From 131 obese subjects in this study, there were 72 (55%) men and 59 (45%) women. Median age: 33 (22-57) years, fasting insulin: 8.90 (2.20-74.50) ìIU/mL, glucagon: 48.10 (7.58-293.90) pq/mL, hs-CRP: 1.90 (0.20-9.50) mg/L, HOMA-IR: 2 (0.50-23.15), and vaspin levels: 0.16 (0.04-1.46) ng/mL. There was a significant positive correlation between HOMA-IR, insulin and glucagon with vaspin (r = 0.20, p = 0.020; r = 0.20, p = 0.022; and r = 0.28, p = 0.001), and a significant negative correlation between hs-CRP and vaspin (r = -0.24, p = 0.005) in obesity. In the path analysis, there was a direct and total negative effect of hs-CRP on vaspin (coefficient = -0.19; p = 0.027 and coefficient = -0.02; p = 0.038).

Conclusion: This study shows a positive association between insulin, glucagon, and HOMA-IR with serum vaspin, while CRP is negatively associated with serum vaspin in obesity.

References

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009;9(1):1–20. https://doi.org/10.1186/1471-2458-9-88/TABLES/2.
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102(30):10610. https://doi.org/10.1073/PNAS.0504703102.
Bagheri M, Farzadfar F, Qi L, Yekaninejad MS, Chamari M, Zeleznik OA, Kalantar Z, Ebrahimi Z, Sheidaie A, Koletzko B, Uhl O, Djazayeri A.. Obesity-Related Metabolomic Profiles and Discrimination of Metabolically Unhealthy Obesity. J Proteome Res 2018;17(4):1452–62. https://doi.org/10.1021/ACS.JPROTEOME.7B00802.
Feng R, Li Y, Wang C, Luo C, Liu L, Chuo F, Li Q, Sun C. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract 2014;106(1):88–94. https://doi.org/10.1016/J.DIABRES.2014.07.026.
Kim JM, Kim TN, Won JC. Association between serum vaspin level and metabolic syndrome in healthy Korean subjects. Metab Syndr Relat Disord 2013;11(6):385–91. https://doi.org/10.1089/MET.2013.0054.
Lavie CJ, Elagizi A, Kachur S, Carbone S, Archer E. Weighing in on obesity prevention and cardiovascular disease prognosis. J Lab Precis Med 2018;3:85–85. https://doi.org/10.21037/JLPM.2018.09.02.
Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Https://Doi.org/101517/13543784173327 2008;17(3):327–33. https://doi.org/10.1517/13543784.17.3.327.
Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi E, Horiguchi CS, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 2012;61(11):2823–32. https://doi.org/10.2337/DB12-0232/-/DC1.
JT, Klöting N, Kovacs P, Kuettner EB, Strater N, Schultz S, Kern M, Stumvoll M, Bluher M, Beck-Sickinger A. Vaspin inhibits kallikrein 7 by serpin mechanism. Cellular and Molecular Life Sciences 2013;70(14):2569. https://doi.org/10.1007/S00018-013-1258-8.
Liu S, Duan R, Wu Y, Du F, Zhang J, Li X, Guo S, Wang M, Zhang Q, Li Y, Li N. Effects of Vaspin on Insulin Resistance in Rats and Underlying Mechanisms. Sci Rep 2018;8(1). https://doi.org/10.1038/S41598-018-31923-3.
Esteghamati A, Noshad S, Mousavizadeh M, Zandieh A, Nakhjavani M. Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance. Diabetes Metab J 2014;38(2):143–9. https://doi.org/10.4093/DMJ.2014.38.2.143.
Yang L, Chen SJ, Yuan GY, Wang D, Chen JJ. Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes. Genet Mol Res 2015;14(3):11356–61. https://doi.org/10.4238/2015.SEPTEMBER.25.2.